



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Bepreve™

Common Name: Bepotastine Besilate

PDL Category: Ophthalmic Antiallergics- Antihistamines

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Optivar®	Preferred
Patanol®	Preferred
Pataday™	Preferred

Summary

Indications and Usage: Treatment of ocular itching associated with allergic conjunctivitis.¹

Mechanism of Action: Direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.¹

Dosage Forms: Ophthalmic Solution: 1.5%

Recommended Dosage: Instill one drop into the affected eye(s) twice a day (BID).¹

Common Adverse Drug Reactions: mild taste following instillation, eye irritation, headache, and nasopharyngitis.¹

Contraindications: None.¹

Manufacturer: ISTA Pharmaceuticals®, Inc.

Analysis: Bepreve™ is a new ophthalmic Histamine₁ Receptor antagonist indicated for the treatment of ocular itching associated with allergic conjunctivitis. In the trials used to gain FDA approval, Bepreve™ was compared only to its vehicle for the treatment of allergic conjunctivitis. Preferred alternatives appear on the Preferred Drug List which are indicated for once daily treatment of allergic conjunctivitis, have similar clinical efficacy, and are more cost effective. Therefore, it is recommended that Bepreve™ be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation: Preferred Drug Recommended Drug
 Non-Preferred Drug Non-Recommended Drug
 Preferred Drug with Conditions

1. Bepreve™ [package insert]. Irvine, CA: ISTA Pharmaceuticals®, Inc.; 2009.